The Ensign Group, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; financial statements are unaudited. Ensign is a holding company whose independent subsidiaries provide post-acute care, skilled nursing, senior living, ancillary services and healthcare real estate. At quarter-end, subsidiaries operated 302 facilities and ancillary operations across 14 states, with approximately 31,169 operational skilled nursing beds and 3,124 senior living units.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $1,010.2 million | $886.8 million | +13.9% |
| Income from operations | $82.2 million | $74.9 million | +9.8% |
| Net income attributable to Ensign | $68.8 million | $59.9 million | +15.0% |
| Diluted EPS | $1.19 | $1.05 | +13.3% |
| Cash provided by operating activities | $35.3 million | $48.3 million | Down $13.0 million |
| Capital expenditures | $29.4 million | $26.7 million | Up $2.8 million |
- Margins: Operating margin was 8.1%, versus 8.4% a year earlier. Net margin was 6.8%, versus 6.7%. Cost of services rose to 79.1% of revenue from 78.5%.
- Cash and working capital: Cash and cash equivalents were $511.8 million at March 31, 2024, versus $509.6 million at year-end 2023. Current assets were $1,088.2 million and current liabilities $709.7 million.
- Debt and leases: Debt principal was approximately $151.4 million, including $149.4 million of HUD-insured mortgages and a $2.0 million note. The $600 million revolving credit facility had no borrowings; $6.3 million of capacity supported letters of credit. The company reported compliance with loan covenants. Operating lease liabilities totaled $1,787.6 million, with $2,775.3 million of undiscounted future lease payments.
- Investments and capital needs: Management reported approximately $122.1 million of investments in addition to cash. Capital expenditures were $29.4 million; approximately $110 million was budgeted for 2024 renovation projects. Management expects cash, operating cash flow and available financing to cover needs for at least the next 12 months.
- Selected non-GAAP measures: Adjusted EBITDA was $112.8 million versus $99.8 million; Adjusted EBT was $100.7 million versus $86.3 million; Standard Bearer FFO was $14.1 million versus $13.2 million. These measures are not substitutes for GAAP results.
Material changes and operating trends
- Revenue growth reflected higher occupancy and daily rates, plus acquisitions. Skilled services revenue increased 13.9%; recently acquired facilities contributed $62.2 million more revenue than in Q1 2023.
- Skilled nursing occupancy based on operational beds rose to 80.1% from 77.9%; same-facility occupancy was 81.0%, which management said exceeded pre-pandemic levels. Patient days increased 10.1% overall.
- Skilled mix declined: skilled patients represented 31.0% of skilled nursing days versus 32.3%, and 49.9% of skilled nursing revenue versus 52.7%. Medicare and Medicaid together accounted for 71.6% of service revenue, down from 73.3%.
- No additional state relief funding was received in Q1 2024. In Q1 2023, $26.4 million was recognized as revenue from state relief programs, including pandemic-related funding.
- Operating cash flow decreased year over year, which management attributed primarily to the timing of wage and benefit payments, partly offset by stronger operating performance. Investing cash use was $34.7 million; financing provided $1.6 million.
- Ensign added five skilled nursing operations during the quarter, adding 591 operational beds. Subsequent to quarter-end, it reported additions of five skilled nursing operations, one long-term acute care hospital and two campus operations.
Outlook, risks and unusual items
- Company guidance: The filing does not provide a specific company financial forecast or quantified earnings guidance. Management described occupancy, acquisition and integration initiatives as priorities and stated that liquidity should support operations for at least 12 months.
- Regulatory and labor outlook: CMS’s FY 2025 proposed skilled nursing payment rule projected a 4.1% aggregate rate increase, subject to finalization. CMS issued a minimum staffing rule on April 22, 2024, after quarter-end; the filing warns it could increase labor costs and affect capacity and profitability. Non-rural facilities face phased requirements, including 24/7 RN coverage and minimum hours of nursing care.
- Legal matters: In January 2024, the company agreed to a $48.0 million settlement of a qui tam civil case concerning medical-director relationships, subject to DOJ and other government review. The company reported no admission of wrongdoing. Separately, a DOJ Civil Investigative Demand received in January 2024 concerns Medicare and Texas Medicaid claims for services allegedly unnecessary or inconsistent with reimbursement requirements, covering January 1, 2016 onward; the company is cooperating and says the outcome and financial impact cannot be predicted.
- Other litigation and reserves: The company intends to appeal a late-2023 Arizona medical-negligence verdict. Accrued litigation was $51.7 million at March 31, 2024; the filing does not clearly state how this balance relates to the settlement. General and professional liability reserves, workers’ compensation and employee health claims depend on actuarial estimates.
- Key business risks: Significant reliance on government reimbursement, changing Medicaid and Medicare rules, audits and potential recoupments, staffing availability and costs, clinical and regulatory compliance, litigation and self-insurance exposure, acquisition integration, and long-term lease commitments. Twenty-two subsidiaries had Medicare reviews scheduled or in process as of quarter-end and the filing date.
- Management reported a $1.849 million long-lived asset impairment in Q1 2024; none was recorded in the comparable quarter. The filing also reported stock-based compensation of $8.2 million versus $6.6 million.
Important facts for investors to verify
- Whether operating cash flow recovers, given lower cash generation despite higher earnings and the timing-related working-capital pressures cited by management.
- Whether occupancy gains can be sustained alongside lower skilled mix, and how changes in acuity and payer mix affect rates and margins.
- The final status, timing and accounting treatment of the $48.0 million settlement, and developments or potential exposure from the separate DOJ investigation.
- The staffing rule’s implementation, any applicable exemptions or legislative changes, and its effect on labor costs, staffing levels and facility capacity.
- Acquisition integration and renovation spending, including the company’s substantial lease obligations and the subsequent additions disclosed after quarter-end.